SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: Having established that in the great majority of advanced‐phase CML patients, SETD2 loss of function is reversible, we wondered whether restoring physiological levels of H3K36me3 by pharmacological targeting of Aurora‐A kinase‐/MDM2‐/proteasome‐mediated degradation of SETD2 might represent a therapeutic strategy.